
Pfizer will apply for emergency use authorization from the FDA within days after final results from its late-stage trial of its COVID-19 vaccine showed it was 95 percent effective. The drugmaker said efficacy of the vaccine developed with German partner BioNTech SE was consistent across age and ethnicity demographics, and that there were no major side effects, a sign that the immunization could be employed broadly around the world. Efficacy in adults over 65 years, who are at particular risk from the virus, was over 94%. The final analysis comes just one week after initial results from the trial showed the vaccine was more than 90% effective.